Scientists in Hong Kong offer new hope into treatment of Huntington's Disease
A research team at the Chinese University of Hong Kong (CUHK) has discovered a new underlying mechanism and possible therapeutic target for Huntington's Disease, a rare, incurable disease that can cause twitching movements and cognitive decline.
Advertisement
The team of the School of Life Sciences at CUHK revealed on Monday that they had found a 4.5-fold increase in the level of a protein called PAPD5 in the brains of patients with Huntington's Disease compared to healthy individuals, which contributed to neuronal apoptosis, or nerve cell death.
Their research showed that blocking the activity of PAPD5 could reduce these harmful effects, opening up new possibilities for developing medication.
The research paper was published in the international journal Nature Communications on April 9.
'We provide a new angle to understand the underlying mechanism. This PAPD5-mediated pathway was first uncovered in our study. It has not been reported before,' said Stephen Chen Zhefan, the assistant professor at the School of Life Sciences at CUHK and the lead author of the paper.
Advertisement
'In addition to strengthening our understanding of the disease mechanisms, we also propose a new target for the future, a therapeutic development against Huntington's Disease.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
30-05-2025
- South China Morning Post
For China to be an education power, Hong Kong universities must stay free
China has laid out its most ambitious education road map to date. The Education Power Construction Plan Outline aims to transform the country into a global education powerhouse by 2035. As the mainland's universities climb up global rankings and research output surges, Hong Kong's role in advancing this vision deserves greater attention. Advertisement Amid rising geopolitical tensions – exacerbated by moves such as US universities cutting ties with select Chinese institutions – Hong Kong's globally connected, academically credible universities stand out. They can serve as platforms for international cooperation that maintain legitimacy in both Chinese and Western contexts. The University of Hong Kong, Chinese University of Hong Kong and Hong Kong University of Science and Technology feature among the world's top 100 . But what sets them apart is their ability to operate bilingually, attract global faculty and forge research partnerships across ideological and geopolitical divides. These capabilities have taken on new importance as governments elsewhere reassess academic collaboration with China. Unlike most mainland institutions, Hong Kong's universities offer familiar legal protections, relatively autonomous governance and robust international networks. This makes them uniquely positioned as credible mediators in scientific, technological and cultural exchanges. China's education strategy emphasises cultivating high-level talent and innovation capacity, especially in strategic sectors like artificial intelligence semiconductors and biotechnology. Hong Kong's institutions are already contributing. HKUST , for instance, plays a key role in robotics and digital technology while HKU advances biomedical research. Advertisement Their partnerships with Hong Kong Science Park and Cyberport create collaboration channels vital to the Greater Bay Area's ambition of becoming a global innovation hub.
South China Morning Post
20-05-2025
- South China Morning Post
Hong Kong's CUHK eyes scholars from US amid higher education turmoil in country
The president of the Chinese University of Hong Kong (CUHK) has said his institution will study how to use research funding to attract top academics who left US institutions amid the Trump administration's battle with higher education in the country. Professor Dennis Lo Yuk-ming also said the recent tariff tensions between China and the US had driven up the prices of equipment and chemicals from the country, and his university found it difficult to procure them for research purposes. Lo, who was installed as the ninth vice-chancellor and president of CUHK in a ceremony on Tuesday, said in his address that Hong Kong was now in an ever-changing era and was constantly facing complex and unexpected clashes. 'As a knowledge hub and cradle of talent, the university has to target, show resilience and be flexible in dealing with storms more than ever before,' he said. Lo said with some academics in the US leaving the country following President Donald Trump's recent clash with elite private universities, his team would study how to offer more research subsidies to attract these foreign scholars. 'I hope CUHK will become their first choice … geopolitics brings crises and opportunities and allows us to have opportunities to hire academics elsewhere,' he said. But he said the university found it harder and more expensive to purchase some equipment and reagents for its Shenzhen Research Institute.
RTHK
19-05-2025
- RTHK
CUHK study finds mainland cancer drug to be effective
CUHK study finds mainland cancer drug to be effective CUHK researchers say the drug D3S-001 has shown promise during a phase 1 trial. Photo: RTHK Chinese University medical researchers on Monday said a multinational study they led has found a mainland-developed cancer drug to be effective in treating tumours. They said the drug D3S-001, from company D3Bio, has shown promise during a phase 1 trial involving patients with cancers of the lung, pancreas and colon that are driven by KRAS-G12C gene mutations. More than 70 percent of those who took part in the trial saw their tumours shrink significantly or disappear altogether, the researchers said. Associate professor at the university's department of clinical oncology, Dr Herbert Loong, said the new drug is more effective than previous treatments. "In the sense that it does inhibit KRAS-G12C at a quicker rate and most likely at a longer duration as well," Loong said. Professor Tony Mok, who chairs the department, said further study is needed. "We are actually looking into a phase three development, most likely we would like to see this compound as a first-line medication," Mok said. The researchers said their findings have been published in the Nature Medicine journal.
